Quest Partners LLC Grows Stake in Vir Biotechnology, Inc. (NASDAQ:VIR)

Quest Partners LLC raised its stake in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) by 142.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,695 shares of the company’s stock after purchasing an additional 7,452 shares during the period. Quest Partners LLC’s holdings in Vir Biotechnology were worth $113,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. Vanguard Group Inc. lifted its stake in Vir Biotechnology by 0.6% in the first quarter. Vanguard Group Inc. now owns 12,375,355 shares of the company’s stock worth $125,362,000 after purchasing an additional 78,216 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Vir Biotechnology by 0.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 813,288 shares of the company’s stock worth $7,238,000 after acquiring an additional 6,359 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in Vir Biotechnology by 4.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 753,073 shares of the company’s stock valued at $7,576,000 after acquiring an additional 31,405 shares during the last quarter. Empowered Funds LLC increased its stake in Vir Biotechnology by 8.2% in the 1st quarter. Empowered Funds LLC now owns 458,044 shares of the company’s stock worth $4,640,000 after buying an additional 34,640 shares during the period. Finally, Jacobs Levy Equity Management Inc. raised its stake in shares of Vir Biotechnology by 5.7% during the first quarter. Jacobs Levy Equity Management Inc. now owns 310,091 shares of the company’s stock valued at $3,141,000 after acquiring an additional 16,615 shares in the last quarter. 65.32% of the stock is owned by institutional investors.

Vir Biotechnology Trading Down 3.0 %

Shares of VIR opened at $7.87 on Tuesday. The stock’s 50 day moving average is $8.89 and its two-hundred day moving average is $9.46. Vir Biotechnology, Inc. has a 12 month low of $7.41 and a 12 month high of $13.09. The firm has a market cap of $1.07 billion, a P/E ratio of -1.96 and a beta of 0.46.

Vir Biotechnology (NASDAQ:VIR) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.13). The firm had revenue of $3.08 million for the quarter, compared to analysts’ expectations of $7.53 million. Vir Biotechnology had a negative return on equity of 30.93% and a negative net margin of 612.40%. Vir Biotechnology’s quarterly revenue was down 19.0% on a year-over-year basis. During the same quarter last year, the firm posted ($1.45) earnings per share. Equities research analysts forecast that Vir Biotechnology, Inc. will post -3.26 EPS for the current year.

Wall Street Analysts Forecast Growth

VIR has been the topic of several recent research reports. Barclays increased their target price on shares of Vir Biotechnology from $27.00 to $28.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Needham & Company LLC boosted their price objective on shares of Vir Biotechnology from $15.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, June 5th. HC Wainwright reiterated a “buy” rating and issued a $110.00 price target on shares of Vir Biotechnology in a report on Tuesday, August 20th. Finally, Morgan Stanley boosted their price objective on Vir Biotechnology from $12.00 to $15.00 and gave the company an “equal weight” rating in a report on Thursday, June 6th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, Vir Biotechnology currently has an average rating of “Moderate Buy” and a consensus price target of $36.80.

Insider Buying and Selling

In related news, Director Janet Napolitano sold 12,190 shares of Vir Biotechnology stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $7.80, for a total transaction of $95,082.00. Following the transaction, the director now owns 11,616 shares in the company, valued at $90,604.80. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 15.60% of the stock is currently owned by company insiders.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand.